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The  uridine  nucleotide  analogue  sofosbuvir  is a selective  hepatitis  C virus  NS5B  polymerase  inhibitor,
active  regardless  of genotype.  We  analyzed  data  on  efﬁcacy  and  safety  of  sofosbuvir,  either  in combina-
tion  with  pegylated  interferon  alfa-2a  and  ribavirin,  or in combination  with  ribavirin  alone  as  part  of  an
interferon  free  regimen  in  more  than  1300  patients.  Treatment  with  sofosbuvir  for  12  weeks in  combi-
nation  with  P/R, in  naïve  genotype  1 patients  was  mainly  studied  in Neutrino.  The  efﬁcacy  of  sofosbuvir
as  part  of  an all-oral  combination  including  ribavirin  alone,  was  explored  in 555  naïve,  ineligible  and
previous  treatment  failure  genotype  2/3  patients.  Rates  of  Sustained  Viral  Response  in genotype  1  and  2
were  higher  than  85%.  For  genotype  3 and 4, a European  study,  Valence,  and  a US  study  on  patients  of
Egyptian  origin  showed  that naïve  patients  are  cured  at high  rates  by the all-oral  combination  given for
24  weeks.  The  efﬁcacy  of  sofosbuvir  plus  P/R  for 12  weeks  in  previous  treatment  failure  genotype  3  has
also  been  demonstrated.  Sofosbuvir-based  combinations  are  safe  and  well  tolerated  without  side  effects
directly  related  to the  drug.  A  large  body  of evidence  suggests  that  sofosbuvir  marks  a revolution  in  HCV
treatment.
©  2014  Editrice  Gastroenterologica  Italiana  S.r.l.  Published  by Elsevier  Ltd.  
Open access under CC BY-NC-ND license.. Introduction
In December 2013, in US, the Food and Drug Administration fully
pproved (10/10) the registration of sofosbuvir for hepatitis C virus
nfection (HCV) treatment [1]. One month later, with a fast-track
rocedure, sofosbuvir was also approved by the European regula-
ory agency (EMA) [2]. Sofosbuvir is an oral HCV-speciﬁc uridine
ucleotide analogue, active against all HCV genotypes, developed
n a program including 13 phase I, 5 phase II and 4 phase III studies
reating more than 3000 HCV infected patients.
Sofosbuvir is a prodrug metabolized intrahepatically from a
onophosphorylated uridine nucleotide to a triphosphorylated
ompound [3]. The active triphosphate, GS461203, competes with
ndogenous uridine triphosphate for incorporation into the grow-
ng HCV ribonucleic acid (RNA) chain by the non-structural protein
B (NS5B) polymerase enzyme and acts as a chain terminator.The  NS5B active site is well conserved across HCV genotypes
xplaining why sofosbuvir shows pangenotypic efﬁcacy [4]. More-
ver, because mutations within the active site limit the enzyme’s
∗ Corresponding author at: Liver Unit, IRCCS “Casa Sollievo della Sofferenza”,
1013  San Giovanni Rotondo, Italy. Tel.: +39 882 416375; fax: +39 882 416271.
E-mail address: a.mangia@tin.it (A. Mangia).
ttp://dx.doi.org/10.1016/j.dld.2014.09.026
590-8658/© 2014 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. Opreplication ability through reduction of virus ﬁtness, viral resis-
tance was not observed in patients who  did not achieve SVR.
2.  Efﬁcacy of sofosbuvir: preamble
The goal of treatment in all infected individuals, regardless of
HCV genotype (G1–6), has been and continues to be the achieve-
ment of a sustained virological response (SVR). This is deﬁned as
HCV RNA undetectable or below the lower limit of quantiﬁcation
(<LLOQ) by highly sensitive quantitative assays after treatment [5].
While in the past SVR was measured 24 weeks (SVR24) after the
end of treatment, in 2013, data from clinical trials demonstrated
that SVR measured at 12 weeks post-treatment (SVR12) is highly
concordant with SVR24 [5,6].
Phase II and III studies have evaluated sofosbuvir in combination
with ribavirin (R) with or without peginterferon (P). The results of
phase II studies demonstrated that sofosbuvir once daily is able to
suppress HCV RNA in genotypes 1, 2, 3, 4, 5 and 6 at the dose of
400 mg  and that genotypes 2 and 3 can be effectively treated with
sofosbuvir and ribavirin with or without peginterferon. Moreover,
they showed that for HCV genotypes 1, 4, and 6 the addition of
peginterferon to sofosbuvir and ribavirin increases the response
rate and allows the duration of therapy to be reduced to 12 weeks.
en access under CC BY-NC-ND license.
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Table 1
Phase II studies: efﬁcacy summary.
Study name Study population SVR
PROTON GT 1, 2 and 3 >90%
SOF + P/R 12 wks
ATOMIC GT1, 4 and 6 >90%
SOF + P/R 12/24 wks
QUANTUM GT 1, 2, 3, 4 53% (12 wks)
SOF + R 12/24 67% (24 wks)
ELECTRON GT 1 84% (GT1)
SOF + R 12 wks 100% (GT2/3)
GT 2 40%  relapse after
monotherapySOF  ± P/R or SOF up to 12 wks
LONESTAR-2 GT  2/3 96%
SOF + P/R 12 wks
SVR, sustained virological response; P, peginterferon; R, ribavirin; SOF, sofosbuvir;
GT,  genotype; wks, weeks.
Fig. 1. Sofosbuvir phase III programs in Genotype 2 and 3 patients: design of the
studies. Abbreviations: Peg-IFN, peginterferon; RBV, ribavirin; SOF, sofosbuvir; GT,180 A. Mangia, V. Piazzolla / Digestive 
Finally, phase II studies have demonstrated that sofosbuvir in
ombination with ribavirin is safe and well tolerated.
. Phase II studies
Six  studies including 758 patients represented the early phase
I program in monoinfected chronic hepatitis C patients, excluding
he transplant setting. Dose, duration and combination regimens
f sofosbuvir and ribavirin with or without peginterferon were
xplored. Non-1 genotypes were not included in every study.
Among  these studies, the P7977-0221 [7] and the PROTON study
8] were dose-ﬁnding. With the exception of the Quantum [9] and
f the Lonestar-2 [13], the phase II studies did not enrol cirrhotic
atients.
. Dose-ﬁnding Phase II studies
In the P7977-0221 study, patients received sofosbuvir 100, 200
r 400 mg  or placebo once daily in combination with ribavirin 1000
r 1200 mg,  on the basis of body weight with or without peginter-
eron -2a 180 g administered subcutaneously once weekly for 4
eeks, followed by additional 44 weeks of P/R [7]. Efﬁcacy analyses
ere conducted in patients receiving at least one dose of study drug
ITT). Active treatment with increasing dosages of sofosbuvir was
ompared to placebo plus P/R for 48 weeks. Rapid Viral Response
RVR) rates ranged from 88% to 94% for sofosbuvir containing regi-
ens. In keeping with RVR rates reported in past studies on dual
herapy, the corresponding rates in the control arm were not higher
han 21%. The study showed that the potency of 200 and 400 mg  of
ofosbuvir was higher than that of 100 mg,  both in terms of rapid
CV RNA decline and of the lower number of virological failures.
The  PROTON study was a double-blind study designed to assess
irological responses to 200 or 400 mg  doses of sofosbuvir in com-
ination with P/R for 12 weeks in naïve non-cirrhotic patients. The
uration of the additional treatment with P/R was of 12 to 36 weeks
epending on undetectable HCV RNA at week 4 and 12 or only at
eek 12. The control group included 26 patients receiving P/R for
8 weeks. As 3 patients in the 200 mg  arm, but none in the 400 mg
xperienced a virological failure after discontinuation of sofosbu-
ir, it was concluded that 400 mg  was the dose to be evaluated in
hase III studies [8]. While P7977-0221 only enrolled genotype 1
atients, the PROTON study included a small cohort of 25 patients
ith HCV genotypes 2 and 3.
. Efﬁcacy of Phase II studies in naïve patients
Efﬁcacy was the primary endpoint in three of the Phase II
tudies: ATOMIC, QUANTUM and ELECTRON [9–11]. Safety and
olerability were investigated in all the studies. Duration of sofos-
uvir treatment for naïve patients with genotype 1, 4, 5 and 6 was
xtended up to 24 weeks in ATOMIC, QUANTUM and ELECTRON
Table 1).
The  ATOMIC study with 332 non cirrhotic patients showed that
he addition of P/R increases the response rates not only in HCV
enotype 1, but also in 4 and 6. Moreover, it showed that 90% SVR
ates were marginally increased by extending treatment duration
rom 12 to 24 weeks or adding 12 weeks of sofosbuvir monotherapy
r sofosbuvir and ribavirin. In patients with genotype 4 and 6, SVR
ates were 82% and 100%, respectively [9].
QUANTUM investigated all-oral combination of sofosbuvir and
BV in genotype 1 patients for 12 or 24 weeks (Fig. 1). Overall SVR
ates of 56% were achieved in genotype 1 with no beneﬁt in extend-
ng treatment with sofosbuvir and ribavirin to 24 weeks. Reducing
reatment duration or decreasing ribavirin dosages reduced treat-
ent efﬁcacy.genotype; wks, weeks.
Another investigator-sponsored study on all-oral combination
was developed at the National Institutes of Health [12]. The study
examined the use of sofosbuvir plus ribavirin in treatment-naïve
patients with chronic HCV genotype 1 infection and unfavourable
baseline characteristics. It was subdivided into two  parts and
included patients with early or moderate ﬁbrosis who received
sofosbuvir plus ribavirin for 24 weeks and patients with geno-
type 1 and all the stages of ﬁbrosis treated either with sofosbuvir
plus weight-based ribavirin or with low (600 mg)  ribavirin dosages,
respectively. In the ﬁrst part of the study, 60% of patients were geno-
type 1a infected, in the second part genotype 1a infected patients
were 72%. 10% of patients in part 1 and 26% in part 2 had stage 3–4
of liver ﬁbrosis. In part 1 SVR was attained in 9 out of 10 patients
(90%) whereas in part 2, low ribavirin dosages were associated
with response rates of 48%, weight-based dosages with 68% SVR.
In this study, a liver biopsy taken in 58% of the study participants,
2 weeks after the end of treatment, showed a signiﬁcant improve-
ment in the HAI inﬂammation score in comparison to the baseline
biopsy.
6. Efﬁcacy of Phase II studies in treatment experienced
patientsThe efﬁcacy of sofosbuvir in 10 genotype 1 patients who had
failed to respond to previous P/R courses was  assessed in the
ELECTRON study [11]. Despite a rapid viral decline, 9 subjects expe-
rienced a relapse after 12 weeks of therapy.
and Liver Disease 46 (2014) S179–S185 S181
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Fig. 2. Sofosbuvir phase III programs in Genotype 2: SVR in patients with cirrhosis.A. Mangia, V. Piazzolla / Digestive 
. Phase II studies on genotype 2 and 3
Naïve, non cirrhotic patients with genotype 2 and 3 infection,
ged about 48, were investigated in the PROTON study. Patients
eceived sofosbuvir 400 mg  and P/R for 12 weeks. Out of 25 patients,
0 were genotype 3 infected and all but 1, who was lost to follow
p, achieved SVR with an overall rate of 92% [8].
The ELECTRON study included 60 naïve patients and 25 treat-
ent experienced with genotype 2 and 3. This study was  initially
esigned to evaluate the minimum duration of peginterferon com-
ination, and alternatively, the efﬁcacy of an all-oral treatment
ased on sofosbuvir and ribavirin. Therefore, sofosbuvir and riba-
irin alone and in combination with peginterferon for 4, 8 and
2 weeks were studied. In a subsequent phase, 3 additional arms
ncluding sofosbuvir and ribavirin alone for 12 weeks, sofosbuvir
onotherapy and sofosbuvir, P/R for 12 or 8 weeks, respectively,
ere added [11]. Efﬁcacy results in 10 patients per arm showed that
he sofosbuvir and ribavirin combination is associated with SVR of
00%. Sofosbuvir monotherapy is associated with the lowest rate of
esponse (60%). All the 30 patients receiving sofosbuvir and P/R for
 variable duration of treatment achieved SVR rates of 100%. Of 39
aïve patients with genotype 3 infection included in the PROTON
nd ELECTRON studies and treated with sofosbuvir and ribavirin
ith any duration of peginterferon, 38 achieved SVR [8,11].
In  this study, 25 genotype 2 and 3 treatment-experienced
atients  were treated with sofosbuvir and ribavirin for 12 weeks.
VR rate in these patients was 68%. The analysis by genotype
emonstrated, 100% SVR rates in 6 genotype 2 and 58% in 19 geno-
ype 3 [11].
The  LONESTAR-2 trial is a single arm open-label study inves-
igating a 12 week regimen of sofosbuvir 400 mg  daily plus
eginterferon -2a 180 mcg  weekly and ribavirin 1000–1200 mg
n treatment-experienced patients with chronic HCV genotype 2
nd 3 infection [12]. Overall 42 of 47 (89%) achieved SVR12 with
nly 2 virologic failures due to relapse. Both relapsers were geno-
ype 3 infected. Of cirrhotic patients, 13 out of 14 genotype 2, and
0 out of 12 genotype 3 attained SVR. This SVR rate is, so far, the
ighest in previous experienced cirrhotics with genotype 3 infec-
ion. These results were used in the EASL guidelines to recommend
he combination of sofosbuvir and P/R for 12 weeks as a ﬁrst option
n patients with genotype 3 [13].
. Summary of sofosbuvir efﬁcacy in Phase II studies
Table 1)
Sofosbuvir plus P/R for 12 weeks achieved rates of SVR of 90%
r higher in treatment naïve genotype 1 patients. All-oral combi-
ations resulted in higher rates of SVR in genotype 2 compared to
, in naïve patients. As shown by Lonestar-2, the combination of
/R and sofosbuvir is associated with SVR rates of 89% in previous
reatment-failure patients with genotype 2 and 3 infection.
.  Phase III clinical development program
.1. Interferon free treatment studies in patients with genotype 2
nd 3 (Table 2)
Three  studies in patients with genotype 2 and 3 evaluated naïve
FISSION), interferon intolerant (POSITRON) and patients who  had
reviously failed peginterferon or interferon plus ribavirin treat-
ent (FUSION) (Fig. 1) [14,15]. The primary endpoint in all thetudies was SVR12, deﬁned as HCV RNA below LLOQ of 25 IU/ml
y Cobas TaqMan assay version 2.0. Patients with cirrhosis repre-
ented 20% of the study population in FISSION and POSITRON and
0% in FUSION.Abbreviations:  SVR, sustained virological response; wks, weeks; IFN, interferon.
FISSION was  a multicenter, randomized, open label, controlled
study. Overall, 499 patients were enrolled in the ratio of 3:1 to
sofosbuvir 400 mg  once daily and weight-based ribavirin for 12
weeks or to peginterferon (180 mcg  administered subcutaneously
once a week) and 800 mg  of ribavirin daily for 24 weeks. The
primary efﬁcacy analysis established a non-inferiority of 15% for
sofosbuvir and ribavirin for 12 weeks versus P/R combination. Of
the included patients, 72% were genotype 3 infected. As 170 of 253
patients treated with P/R for 24 weeks and 162 of 243 treated with
sofosbuvir and ribavirin for 12 weeks achieved SVR, the rates of
SVR were identical for patients receiving all-oral regimen for 12
weeks and patients receiving P/R for 24 weeks (67%). Therefore,
the primary efﬁcacy endpoint of non-inferiority was met.
In  the sofosbuvir and ribavirin arm, all but 1 treatment failure
(<1%) were due to a relapse (30%). In the remaining 17 of 243 and 8
of 253 patients, respectively, lack of SVR was due to loss to follow
up or consent withdrawal. By contrast, in the P/R arm, 7% of patients
had virological failure, and an additional 33%, a relapse.
By  multivariate analysis, factors associated with higher
response rates to IFN-free regimen were genotype 2, female gen-
der and absence of cirrhosis. The analysis of genotype 2 patients
showed that rates of SVR in patients receiving an all-oral regi-
men were signiﬁcantly higher than those attained in the control
P/R group (97% vs. 78%). Among genotype 3 patients, rates of SVR
were 56% and 63%, after sofosbuvir and ribavirin or, P/R respec-
tively. Multivariate analysis showed that cirrhosis was the main
negative predictor of response in genotype 3, but not in genotype
2 infected patients (Fig. 2). Indeed, in patients with cirrhosis, SVR
was 91% in genotype 2 and 34% in genotype 3 patients. The 92%
response rate was  observed in genotype 2 cirrhotic patients (Fig. 2)
whereas a 62% rate was registered in those receiving the standard
P/R treatment. For patients with genotype 3 and cirrhosis, rates of
SVR were comparably low after sofosbuvir and ribavirin or P/R (30%
vs. 34%). Based on this evidence, genotype 3 infections appears to
be the new challenge.
POSITRON is a multicenter, randomized, double-blind, placebo-
controlled study in patients IFN intolerant (9%) or ineligible (44%)
or unwilling to take interferon (47%). Intolerance was  deﬁned
on the basis of ﬂu-like syndrome (32% of cases), psychiatric dis-
eases (20%), thrombocytopenia (16%) and local adverse reactions
(12%). Interferon ineligible patients were those with psychiatric ill-
ness (57%) autoimmune diseases (19%) and diabetes (5%). Patients
were randomized in ratio of 3:1 to receive sofosbuvir 400 mg once
daily and ribavirin according to body weight or placebo for 12
weeks. Patients in the placebo group were rolled over into an
open label study of sofosbuvir and ribavirin. Either naïve (81%) or
treatment-experienced (19%) patients were included, of these 51%
had genotype 2 and 49% genotype 3.
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Table 2
Phase  III studies: efﬁcacy summary.
Study name Overall efﬁcacy GT 1 GT 4,5,6 GT 2 GT 3
SOF + P/R 12 wks (NEUTRINO) 90% 89% 97% – –
SOF  + R 67%  – – 97% 56%
P/R  (FISSION) 67% 78% 63%
SOF  + R 78% – – 93% 61%
Placebo  (POSITRON) 0 0 0
SOF  + RBV
12 wks  50% – – 86% 30%
16  wks  (FUSION) 73% 94% 62%
SOF + RBV
12 wks  – – –
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VR, sustained virological response; P, peginterferon; R, ribavirin; SOF, sofosbuvir; 
The primary efﬁcacy analysis showed rates of SVR of 78% in 207
atients receiving sofosbuvir and ribavirin and of 0 in 71 patients
ho received placebo. In the sofosbuvir and ribavirin arm, 46 of 207
22%) of patients who did not achieve SVR were relapsers and 4 (2%)
ere lost to follow up. Genotype 2 patients achieved SVR in 93% of
ases (Fig. 2), while genotype 3 in 61%. Overall, patients with cir-
hosis achieved lower SVR rates than non cirrhotics (61% vs. 81%).
his difference was largely driven by genotype 3 infection, associ-
ted with rates of 21% in cirrhotics and of 68% in non-cirrhotics. By
ontrast, in patients with genotype 2, SVR rates were comparably
igh regardless of cirrhosis (94% vs. 92%) (Fig. 2). By multivariate
nalysis, genotype 2 had higher response rates than genotype 3.
redictors of response were cirrhosis and genotype [16].
FUSION  is a multicenter randomized, controlled, double blind
tudy evaluating efﬁcacy and safety of sofosbuvir and ribavirin
reatment for 12 or 16 weeks in patients who failed a previ-
us course of interferon-based treatment (either relapsers or non
esponders). Patients were randomized 1:1. Since re-treatment
ith peginterferon is not recommended for these patients, a his-
orical control rate of 25% was considered. 103 patients were
andomized for 12 weeks and 98 for 16 weeks to sofosbuvir 400 mg
rally, daily and ribavirin on the basis of body weight. In a sec-
ndary analysis, the different treatment durations were compared.
enotype 3 was present in 63% of patients, cirrhosis, in 34%. In
he vast majority of patients (73%) prior treatment failure was due
o relapse. Combination treatment for 12 weeks was associated
ith 50% rates of SVR, while a treatment duration of 16 weeks was
ssociated with 73% response rates. Both rates were higher than
he pre-speciﬁed 25% of the historical control. Relapse accounted
or all the virological failures as out of 50 patients who failed to
chieve SVR after 12 weeks of therapy, 47 were relapser and 3
ere lost to follow up; after 16 weeks, 26 of 95 patients relapsed.
y multivariate analysis, genotype 2 was associated with higher
ates of SVR (Fig. 2). Patients with genotype 2 achieved compara-
le rates of SVR when treated for 16 or for 12 weeks (94% vs. 86%);
y contrast, patients with genotype 3 fared best with 16 weeks
f treatment, as rates of SVR were 62% vs. 30%. After 12 weeks
f treatment, patients with cirrhosis achieved SVR rates of 31% as
ompared to 61% observed in non cirrhotics. After 16 week, SVR
as 66% in cirrhotics and 76% in non cirrhotics. Cirrhotic genotype
 patients attained SVR rates of 60% and 78% after 12 and 16 weeks
f treatment, respectively. 61% of genotype 3 patients with cirrho-
is attained SVR after 16 weeks, compared to only 19% after 12
eeks of treatment. The difference in response rates between cir-
hotic and non cirrhotic patients with genotype 3 was larger after
2 weeks than after 16 weeks. On the basis of these results, the
ALENCE study was conducted to evaluate possible increases in
esponse rates with extended duration of treatment with sofosbu-
ir and ribavirin.–
notype; wks, weeks.
This phase III study was performed in Europe only, involving
either treatment naïve or experienced genotype 2 and 3 patients
[17]. About 20% of the patients were cirrhotics. Initially, patients
were randomized to receive sofosbuvir or ribavirin or placebo for
12 weeks, regardless of genotype. Based on the ﬁrst results attained
on treatment, the trial was un-blinded and the placebo group
terminated. Treatment duration for patients with genotype 3 was
extended to 24 weeks, while patients with genotype 2 continued
on sofosbuvir plus ribavirin for 12 weeks. The study included 73
genotype 2 patients who were treated for 12 weeks and 250 geno-
type 3 patients treated for 24 weeks. Of these patients 58% were
treatment experienced.
Genotype  2 patients attained SVR rates of 93%, genotype 3 rates
of 85% (Fig. 2). Treatment experienced patients with HCV genotype
3 infection and cirrhosis who  received sofosbuvir plus ribavirin for
24 weeks had a SVR rate of 62%. No cases of on-treatment virological
failure were observed in this as in all the other sofosbuvir-based
trials. Five of 73 genotype 2 patients (6.5%) and 38 of 250 genotype
3 patients (15%) experienced a relapse.
The study conﬁrmed that extending the treatment duration
improves the outcome of treatment, but also showed that previous
experienced genotype 3 remain a challenging group.
9.2.  Peginterferon studies in patients with genotype 1, 4, 5, 6
NEUTRINO  is a multicenter, single group, open-label study eval-
uating efﬁcacy of sofosbuvir 400 mg  daily and P/R for 12 weeks in
327 naïve patients with genotype 1, 4, 5 and 6. The primary efﬁcacy
analysis evaluated the superiority of SVR versus a historical con-
trol group rate of 60%, calculated on the basis of the results of the
ADVANCE and SPRINT-2 studies, (based on telaprevir and bocepre-
vir triple combination) [19,20], the response rates were adjusted
for the expected proportion of subjects with cirrhosis included in
the NEUTRINO (approximately 20%). The safety proﬁle of the short
course adopted in the NEUTRINO was  also investigated. Of 327
patients enrolled, the vast majority was infected with subtype 1a
(69%), 11% were genotype 4, 5 and 6. Fifty four (17%) patients had
cirrhosis, 71% were non CC.
Over 99% of patients achieved RVR and end of treatment
response. 90% (295 of 327 patient) achieved SVR, 10% (32 patients)
did not; this response rate was signiﬁcantly higher than the SVR
rate considered for the historical control. Thirty two  patients failed
to achieve SVR (9%), 28 of these due to a relapse. The remaining 4
patients were either lost or withdrew consent (1%). No virological
failure was observed. SVR rates were 92% in genotype 1a, 82% in
genotype 1b, 96% in genotype 4 and 100% in genotype 5 and 6. By
multivariate analysis, IL28B CC genotype and absence of cirrhosis
were independent predictors of SVR. Overall, 98% of patients with
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C genotype achieved SVR compared with 87% of non CC. SVR in
atients with compensated cirrhosis was 80%.
.3. IFN free regimens in patients with genotype 4
To  evaluate safety and efﬁcacy of sofosbuvir and ribavirin in
atients with HCV genotype 4, 60 subjects with Egyptian ancestry
nd chronic HCV genotype 4 infection either naïve or treatment
xperienced were selected and randomized to 12 or 24 weeks of
reatment with sofosbuvir and ribavirin [21]. Cirrhosis was  diag-
osed in 23% of cases. The treatment-naïve patients had higher SVR
ates than the treatment-experienced (89% vs. 71%). The short dura-
ion of treatment was associated with lower response rates in both
aïve (79% vs. 100%) and treatment-experienced (59% vs. 87%). In
atients with cirrhosis, response rates were 100% after 24 weeks in
oth naïve and experienced.
0.  Re-treatment studies
Re-treatment  of patients who had failed a previous treatment
ourse with P/R in combination with a protease inhibitor with
r without the NS5a inhibitor (ledipasvir) or the non-nucleoside
S5b polymerase inhibitor (tegobuvir) with sofosbuvir plus P/R
as recently shown to be successful [22]. The study by Pol et al.
ncluded ﬁfty seven genotype 1 patients. The majority were male
72%), genotype 1a (93%) and IL28B non CC (95%). A SVR of 96%
22/23) was reported for patients who reached week 4 of follow up
22].
Re-treatment regimens containing sofosbuvir plus peginter-
eron -2a and ribavirin were employed to re-treat patients with
enotype 2 and 3 who had experienced a failure in FISSION, FUSION
nd POSITRON. A study performed by Esteban et al. showed that re-
reatment of patients already treated with sofosbuvir is possible
23]. This triple combination regimen for 12 weeks was compared
o 24 weeks of sofosbuvir and ribavirin. Numbers were small,
owever, after 12 weeks of P/R and sofosbuvir, response rates for
enotype 2 patients were 100%, after 24 weeks of all-oral regimen
hey were 50%; corresponding rates in genotype 3, were 91% and
3%. Patients with genotype 3 and cirrhosis were best served by
riple combination rather than a dual combination of sofosbuvir
nd ribavirin (88% vs. 47%) [23].
1. Safety and tolerability
The  safety of sofosbuvir-containing regimens was  studied in 778
atients from phase II and in 991 from phase III trials. In doses of
00 mg  once daily, the drug has been shown to be safe and generally
ell tolerated. When used in combination, adverse reactions are
ostly attributable to the concurrent use of ribavirin or P/R.
2.  Safety and tolerability in phase II studies
The safety proﬁle of sofosbuvir and ribavirin combination for
p to 24 weeks was evaluated in phase II studies. Patients were
ssessed for Adverse Events (AEs) and laboratory abnormalities
merging during treatment, starting from the ﬁrst dose of study
rug through 30 days after the last dose of any study drug. AEs were
ssessed by the investigator as mild or moderate (grade 1 and 2), or
evere (grade 3). Grade 4 and 5 were deﬁned as life-threatening or
atal. Serious adverse events were those leading to hospitalization,
r other medically signiﬁcant events or death.Sofosbuvir-based regimens were shown to be safe and well
olerated [24]. In combination, Sofosbuvir did not result in addi-
ional AEs when compared with AEs reported with ribavirin or P/R.
ndeed, the most common side effects reported in patients treatedver Disease 46 (2014) S179–S185 S183
with  sofosbuvir and ribavirin or sofosbuvir and P/R were those
known to be related to ribavirin and or peginterferon.
Overall, few side effects of moderate intensity occurred in
patients treated with IFN-free regimens. Those not associated with
laboratory abnormalities were not speciﬁc, including fatigue and
headache. Haematological abnormalities including anaemia
and neutropenia were more frequent in studies including
peginterferon. However, grade 3 neutropenia developed in
only 22% of subjects receiving sofosbuvir and P/R.
Few serious adverse events (SAEs) were reported in Phase II
studies and no SAEs were attributable to sofosbuvir. Only 1% of
patients receiving sofosbuvir and ribavirin for 24 weeks as com-
pared to 10% of those receiving sofosbuvir and P/R for 24 weeks
developed side effects leading to treatment discontinuation. In
patients receiving P/R and sofosbuvir combination the correspond-
ing rates were 4% and 10%.
13. Safety and tolerability in phase III studies
The favourable safety proﬁle of sofosbuvir was  conﬁrmed in
naïve, ineligible and prior failures genotype 2 and 3 patients, in
phase III studies FISSION, POSITRON and FUSION. When compared
to P/R in FISSION, AEs registered with sofosbuvir and ribavirin
were fewer than those reported in the peginterferon contain-
ing regimen. In studies on all-oral regimens, AEs were consistent
with those associated with ribavirin treatment. For the fourth
phase III study, the NEUTRINO, the safety analysis was  based on
12 week combination of sofosbuvir plus P/R in genotype 1. Side
effects were predominantly neutropenia and ﬂu-like syndrome.
No additional AEs related to sofosbuvir were registered (Table 3).
The most frequently reported AEs in all treatment arms were
fatigue, headache, nausea, chills, insomnia and arthralgias and were
associated with regimens containing peginterferon. Most were
considered by the investigators to be mild to moderate and most
resolved.
14. Safety of sofosbuvir and ribavirin as all-oral regimen
Across  the sofosbuvir clinical program, the incidence of AEs
leading to permanent discontinuation of treatment was not higher
than 1% in all sofosbuvir containing regimens and lower than the
rate registered in the placebo group in the Positron study (4%) or
in P/R control arm in the FISSION study (11%). In the FUSION study,
the extended duration of all-oral combination from 12 to 16 weeks
was not associated with higher rates of AEs. The number of patients
who had an AE ranged from 86% to 89% in sofosbuvir and ribavirin
arms in phase III studies, but increased to 96% in P/R arm in FISSION.
The most commonly reported AEs were fatigue, nausea, insomnia,
headache, diarrhoea, rash/pruritus, irritability and inﬂuenza-like
symptoms; the ﬁrst three were reported both in the sofosbuvir plus
ribavirin and in the placebo group.
Few SAEs were reported in the FISSION, POSITRON and FUSION
studies. Hepatocellular carcinoma (3 patients), pyrexia and celluli-
tis (2 patients each) were the only SAEs reported in more than 1
patient during sofosbuvir and ribavirin treatment.
Laboratory side effects included haematological and biochem-
ical abnormalities. Haemolytic anaemia associated with ribavirin
was observed in all RBV treatment groups. However, the percentage
of subjects developing anaemia on sofosbuvir and ribavirin com-
bination was  9% after 12 weeks and 5% after 16 weeks. Overall
anaemia occurrence ranged from 4 to 21% of cases treated with
sofosbuvir and ribavirin regardless of peginterferon. Less than 2%
of patients had Hb levels ≤8.5 g/dl.
In FISSION, all the common side effects, except anaemia and
dizziness, were less frequent in the sofosbuvir and ribavirin arm
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Table 3
Adverse events reported by >15% of patients in phase III studies.
NEUTRINO FISSION POSITRON FUSION
PEG-IFN
RBV
Pts No. 327
SOF
RBV
Pts  No. 256
SOF/RBV
IFN
Pts  No. 243
SOF
RBV
Pts  No. 207
Placebo
Pts  No. 71
SOF
RBV  (12 wks)
Pts  No. 103
RBV
SOF  (16 wks)
Pts  No. 98
Fatigue 192(59) 92  (36) 134  (55) 91  (44) 17  (24) 46 (45) 46 (47)
Headache  118 (36) 64 (25) 108 (44) 43 (21) 14 (20) 26 (25) 32 (33)
Nausea  112 (34) 46 (18) 70 (28) 46 (22) 13 (38) 22 (21) 20 (20)
Insomnia  81 (25) 31 (12) 70 (28) 39 (19) 3 (4) 21 (20) 28 (29)
Anaemia  68 (21) 20 (8) 28 (12) 27 (13) 0 11 (11) 4 (4)
Diarrhoea  38 (12) 23 (9) 42 (17) 19 (9) 4 (6) 15 (15) 6 (6)
Irritability  42 (13) 25  (10) 40  (16) 19  (9) 1  (1) 15  (15) 11 (11)
Loss  of appetite 58 (18) 17  (7) 44  (18) 7  (3) 7  (10) 9 (9) 5 (5)
Flu-like  symptoms 51 (16) 7 (3) 44 (17) 8 (4) 2 (3) 1 (1) 3 (3)
Chills  54 (16) 7 (3) 43 (18) 7 (3) 1 (1) 2 (2) 0
Pyrexia  58 (18) 6 (2) 33 (14) 9 (4) 0 4 (4) 3 (3)
Rash  59 (18) 23 (9) 43 (18) 18 (9) 6 (8) 7 (7) 12 (12)
Myalgia  45 (14) 21 (8) 40 (16) 6 (3) 0 8 (8) 9 (9)
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EG-IFN, peginterferon; RBV, ribavirin; SOF, sofosbuvir; Pts, patients; wks, weeks; N
han in the P/R. In this study, <2% of patients on sofosbuvir and
ibavirin against 11% of patients in the control arm discontinued
reatment due to side effects.
In  FUSION, no patients in the 16 week duration arm discontin-
ed treatment. In the sofosbuvir and ribavirin 12 or 16 week groups,
rade 3 hyperglycaemia was registered in up to 6% of patients,
eﬂecting the 8–16% rate of patients with diagnosis of diabetes
articipating in these studies. In all-oral regimens, no effect on
eutrophil and platelets counts was observed. Prevalence of bio-
hemical abnormalities ranged from 0% to 6%.
A grade 3 increase in bilirubin levels was registered in 2%
f patients receiving sofosbuvir and ribavirin and appears to be
elated to haemolytic anaemia. In these studies, no patients had
rade 4 increase in bilirubin.
The safety proﬁle of the VALENCE study showed a 1% rate
f treatment discontinuation due to AEs, regardless of treatment
uration. The safety proﬁle was consistent with that of ribavirin
ithout additional AEs associated with extended treatment dura-
ion.
A combined analysis of 1639 patients from all phase III studies
onﬁrmed that the safety proﬁle of sofosbuvir is consistent with
hat of the agent with which it is administered [24].
5.  Safety of sofosbuvir, ribavirin and peginterferon
egimens
With this combination, SAEs registered in more than 1 patient
ere anaemia, leucopoenia and pyrexia. 95% of patients had at least
able 4
afety proﬁle in patients with cirrhosis enrolled in phase III studies.
Neutrino Naïve
GT1,4,5,6
Fissio
GT2/3
Any AE 51 (96) 41 (82
Grade  ≥3 6 (17) 6 (12
Grade  ≥2 36 (67) 18 (36
SAE  51 (94) 33 (66
Grade  >3 8 (15) 1 (2)
Grade  >2 31 (57) 14 (28
SAE  1 (2) 2 (4)
Treatment  related SAE 0 0 
AE  leading to discontinuation of Sofosbuvir 1 (2) 1 (2)
AE, severe adverse events; AE, adverse event; IFN, interferon; GT, genotype.0 0 1 (<1) 0
mber.
one AE and 15% had a grade 3 AEs including anaemia (23%), neu-
tropenia (20%), fatigue (59%), headache (36%), insomnia (25%) and
nausea (34%).
AEs  leading to treatment discontinuation were reported in 5 of
327 patients (2%): anaemia was the only AE registered in 2 patients.
Laboratory adverse events were mostly haematological abnor-
malities consistent with the bone marrow suppressive effect of
peginterferon and haemolytic anaemia induced by ribavirin. Riba-
virin dose reduction for Hb levels < 10 was  required in 20% of
patients, <1% of patients discontinued treatment due to anaemia
and three patients received blood transfusions due to anaemia.
Neutropenia resulted in peginterferon dose modiﬁcation in 16% of
patients with only one patient discontinuing treatment due to a
neutrophil count <500/mm3.
No more than 3% of patients developed other biochemical abnor-
malities. The number of grade 3 and 4 chemistry abnormalities was
low, 2% of patients had ALT increase (grade 3) and 2% of patients
had hyperglycaemia.
16.  Safety and tolerability in cirrhotic patients
Emerging data show that sofosbuvir is safe even in advanced,
decompensated cirrhosis. In the SPARE study, no patients dis-
continued treatment, 1 (4%) and 5 (20%) patients receiving
weight-based or low doses of ribavirin developed grade 3–4 SAEs.
Eight and 4 patients had anaemia, respectively. In the NEUTRINO
study, rates of AEs were comparable between cirrhotic and non cir-
rhotic patients. Only one out of 54 patients with cirrhosis included
n  Naïve Positron  IFN-ineligible
GT2/3
Fusion  treatment
experienced
GT2/3
) 30 (97) 31 (86) 28 (88)
) 2 (7) 4 (11) 2 (6)
) 14 (45) 17 (47) 17 (53)
) 26 (6) 26 (72) 23 (72)
 0 2 (6) 1 (3)
) 7 (23) 11 (31) 11 (34)
 2 (6) 4 (11) 2 (6)
0 0 0
 2 (6) 0 0
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taining regimens for HCV genotype 2 and 3 infected patients who failed priorA. Mangia, V. Piazzolla / Digestive 
n the NEUTRINO discontinued treatment due to side effects. Com-
arably, of 149 cirrhotic patients included in FISSION, FUSION
nd POSITRON, only 2% discontinued treatment. Table 4 illustrates
dverse events in cirrhotics enrolled in Phase III studies. This good
afety proﬁle has made it possible to extend treatment to a greater
umber of patients.
7.  Summary on safety and tolerability results
The safety proﬁle of sofosbuvir, either in combination with P/R
r in combination with ribavirin alone in all-oral regimen, was
hown to be excellent. The majority of clinical adverse events were
f mild to moderate severity. No speciﬁc AE related to sofosbuvir
as registered across the different genotypes and in patients with
r without cirrhosis. SAE were more common in patients receiving
egimens containing peginterferon.
8. Conclusions
Sofosbuvir represents an important therapeutic advance and
arks a new era of all-oral regimens for HCV infection. The sofos-
uvir revolution started in genotype 2 and 3 patients. Genotype 2
atients were curable with the ﬁrst all-oral regimen at very high
ates after only 12 weeks of therapy. Rates of response compara-
le to those of P/R without the interferon-related side effects were
ttained with this all-oral combination in genotype 3. In patients
ith genotype 1, sofosbuvir plus P/R achieves SVR rates compara-
le to or higher than those reported with PI. High response rates
ere attained in genotype 4, 5 and 6. Oral sofosbuvir was generally
ery well tolerated and able to overcome the safety limitations of
ast regimens. Patients who were previously excluded from treat-
ent, due to interferon contraindications, can now receive antiviral
reatment.
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